Literature DB >> 15610712

Melanoma of the head and neck.

Terry A Day1, Joshua D Hornig, Anand K Sharma, Frank Brescia, M Boyd Gillespie, Deanne Lathers.   

Abstract

Staging of cutaneous melanoma has changed in recent years with an increased emphasis upon thickness and ulceration on prognosis of early stage disease. Cutaneous melanoma of the head and neck is treated with complete surgical resection in early stage disease. Resection margins are determined by the size, depth, and presence of satellite lesions. Evaluation for regional and distant metastatic disease is necessary in all cases of advanced stage disease. Sentinel lymph node biopsy and possible parotidectomy and neck dissection should be considered in head and neck cutaneous melanomas greater than 1 mm in thickness or with ulceration. Adjuvant therapy may be indicated in advanced primary, nodal, and metastatic disease. Mucosal melanoma of the head and neck remains a difficult disease to treat, with high locoregional recurrence rates and poor prognosis despite aggressive therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15610712     DOI: 10.1007/s11864-005-0010-5

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  68 in total

1.  Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma.

Authors:  E K Rofstad
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma.

Authors:  C J O'Brien; K Petersen-Schaefer; G N Stevens; P C Bass; P Tew; V J Gebski; J F Thompson; W H McCarthy
Journal:  Head Neck       Date:  1997-10       Impact factor: 3.147

3.  Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia.

Authors:  Philippa Youl; Joanne Aitken; Nicholas Hayward; David Hogg; Ling Liu; Norman Lassam; Nicholas Martin; Adèle Green
Journal:  Int J Cancer       Date:  2002-03-01       Impact factor: 7.396

4.  Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.

Authors:  Sanjiv S Agarwala; John Glaspy; Steven J O'Day; Malcolm Mitchell; John Gutheil; Eric Whitman; Rene Gonzalez; Evan Hersh; Lynn Feun; Robert Belt; Frank Meyskens; Kristoffer Hellstrand; Diana Wood; John M Kirkwood; Kurt R Gehlsen; Peter Naredi
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

5.  Significant risk of a second melanoma in patients with a history of melanoma but no further predisposing factors.

Authors:  Dorothee Nashan; Burak Kocer; Meinhard Schiller; Thomas Luger; Stephan Grabbe
Journal:  Dermatology       Date:  2003       Impact factor: 5.366

6.  Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine.

Authors:  Ramon Vilella; Daniel Benitez; Jordi Milà; Antoni Vilalta; Ramon Rull; Francisco Cuellar; Carles Conill; Sergi Vidal-Sicart; Josep Costa; Eva Yachi; Josep Palou; Josep Malvehy; Susana Puig; Rosa Marti; Begoña Mellado; Teresa Castel
Journal:  Int J Cancer       Date:  2003-09-10       Impact factor: 7.396

7.  Treatment of cutaneous melanoma of the face by Mohs micrographic surgery.

Authors:  Tasha N Bienert; Martin J Trotter; John P Arlette
Journal:  J Cutan Med Surg       Date:  2002-11-27       Impact factor: 2.092

8.  Constitutional and environmental risk factors for cutaneous melanoma in an Italian population. A case-control study.

Authors:  Maria Concetta Fargnoli; Domenico Piccolo; Emma Altobelli; Federica Formicone; Sergio Chimenti; Ketty Peris
Journal:  Melanoma Res       Date:  2004-04       Impact factor: 3.599

9.  Risk factors for malignant melanoma in an Icelandic population sample.

Authors:  Vilhjalmur Rafnsson; Jon Hrafnkelsson; Hrafn Tulinius; Bardur Sigurgeirsson; Jon H Olafsson
Journal:  Prev Med       Date:  2004-08       Impact factor: 4.018

10.  Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.

Authors:  G C de Gast; D Batchelor; M J Kersten; F A Vyth-Dreese; J Sein; W F van de Kasteele; W J Nooijen; O E Nieweg; M A de Waal; W Boogerd
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

View more
  2 in total

1.  Lymphatic drainage patterns in oral squamous cell carcinoma: findings of the ACOSOG Z0360 (Alliance) study.

Authors:  Roger W Farmer; Linda McCall; Francisco J Civantos; Jeffrey N Myers; Wendell G Yarbrough; Barbara Murphy; Miriam O'Leary; Robert Zitsch; Barry A Siegel
Journal:  Otolaryngol Head Neck Surg       Date:  2015-03-06       Impact factor: 3.497

2.  High-dose proton beam therapy for sinonasal mucosal malignant melanoma.

Authors:  Hiroshi Fuji; Shusuke Yoshikawa; Masako Kasami; Shigeyuki Murayama; Tetsuro Onitsuka; Hiroya Kashiwagi; Yoshio Kiyohara
Journal:  Radiat Oncol       Date:  2014-07-23       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.